With a market cap of $717 billion, Eli Lilly (LLY) is one of the world’s largest pharmaceutical companies. Lilly is well-known for its innovative drug pipeline and longstanding presence in the global healthcare industry. Its core focus areas include diabetes, obesity, oncology, immunology, neuroscience, and cardiovascular and pain management.
Last week, Goldman Sachs analyst Asad Haider upgraded Eli Lilly stock to a “Buy” from a “Neutral” rating, citing a compelling blend of strategic positioning and growth potential in the anti-obesity drug market as key reasons for his optimistic outlook. Eli Lilly’s stock is down 3.9% in the year to date, while the S&P 500 Index ($SPX) is down 9.2%. The stock is also down more than 23% from its 52-week high, led by the overall market volatility.
